 |
|
|
| |
Saquinavir/r 500mg Pills Once or Twice Daily: efficacy, lipids, ALT
|
| |
| |
Reported by Jules Levin
8th Intl Congress on Drug therapy in HIV, Glasgow, UK, Nov 12-16, 2006
A Comparison of Lipid & Hepatic Parameters in Patients Treated with SQV/r in QD or BID Dosing: IPanema Cohort
E Ortega et al, H General de Valencia. Roche Farma, Spain.
532 patients were included in this study. 83% SQV/r bid vs 17% SQV/r once daily; 60% Invirase 500mg vs 40% Invirase 200mg.
BID dose (n=441): 69% male, 40% prior AIDS diagnosis; 55% IVDU; Mean age: 42 yrs; time on treatment: 13.2 months.
QD dose (n=91): 68% male; 38% prior AIDS diagnosis; 53% IVDU; mean age: 41 yrs; time on treatment: 8 mopnths.
No significant baseline differences in both groups except in prior number of ART: BID 5.5 ART vs QD 6.4 ART (p<0.05).
The authors Concluded: "After a mean of 13.2 months on saquinavir/r treatment with either QD or BID regimens, a good virological and immunologival was seen without impairing lipid, hepatic and glucose levels".
|
| |
|
|
|
|
|
